Grape seed extract and HbA1c have become a growing focus of research interest, as scientists explore whether this polyphenol-rich supplement might support blood glucose control in people with type 2 diabetes or prediabetes. Derived from the seeds of Vitis vinifera, grape seed extract (GSE) contains concentrated oligomeric proanthocyanidins (OPCs) with antioxidant and anti-inflammatory properties. Some small clinical trials suggest a modest effect on fasting glucose and HbA1c, but the evidence remains limited. This article examines what the research shows, how GSE may work, its safety profile, and how it fits within NHS and NICE guidance on diabetes management.

What Is Grape Seed Extract and How Might It Affect Blood Sugar?

Grape seed extract is a concentrated source of OPCs that may improve insulin sensitivity and slow carbohydrate absorption by inhibiting digestive enzymes, though these mechanisms are based largely on preclinical studies and have no MHRA-licensed indication for glycaemic control.

Grape seed extract (GSE) is a concentrated supplement derived from the seeds of Vitis vinifera, the common grape vine. It is rich in oligomeric proanthocyanidins (OPCs), a class of polyphenolic compounds with antioxidant, anti-inflammatory, and vasodilatory properties. These bioactive compounds are also found in smaller quantities in red wine, grape juice, and grape skin, but the extract form provides a far more concentrated dose.

Researchers have proposed several pathways through which GSE might influence blood glucose regulation, though it is important to emphasise that these mechanisms are largely based on preclinical (cell-based and animal) studies, and their relevance to human glycaemic control has not been established. OPCs may enhance insulin sensitivity by reducing oxidative stress in peripheral tissues, which is known to impair insulin receptor signalling. Some laboratory studies also suggest that proanthocyanidins can inhibit certain digestive enzymes — including alpha-amylase and alpha-glucosidase — thereby slowing the breakdown and absorption of dietary carbohydrates. This is broadly the same pathway used by alpha-glucosidase inhibitors such as acarbose; however, acarbose is not routinely used in UK clinical practice, and any enzyme-inhibiting effect observed with GSE in laboratory settings should not be taken to imply equivalence to a licensed medicine. GSE has no MHRA-licensed indication for glycaemic control.

GSE may also support endothelial function and reduce low-grade systemic inflammation, both of which are implicated in insulin resistance and the progression of type 2 diabetes. However, translating these preclinical findings to meaningful clinical outcomes — including HbA1c reduction — requires robust human evidence, which remains limited.

Evidence on Grape Seed Extract and HbA1c Levels

Some small RCTs report modest, statistically significant reductions in HbA1c with GSE supplementation, but limitations including small sample sizes, short durations, and heterogeneous formulations mean firm clinical conclusions cannot be drawn.

HbA1c (glycated haemoglobin) is the gold-standard marker for assessing long-term blood glucose control, reflecting average blood sugar levels over the preceding two to three months. In the UK, HbA1c is reported in mmol/mol (IFCC units); a level of 48 mmol/mol (6.5%) or above is used to diagnose type 2 diabetes, and a target of 48 mmol/mol or below is commonly set for people managed with lifestyle measures alone (NICE NG28). Even modest reductions in HbA1c — in the region of 5–11 mmol/mol (0.5–1.0%) — are associated with a meaningfully reduced risk of diabetes-related complications, including retinopathy, nephropathy, and cardiovascular disease, as demonstrated in landmark studies such as the UKPDS and DCCT/EDIC.

The question of whether GSE can meaningfully lower HbA1c in humans has attracted growing scientific interest, though the evidence base remains modest. Several small-scale randomised controlled trials (RCTs) have investigated GSE supplementation in individuals with type 2 diabetes or metabolic syndrome, with some reporting statistically significant reductions in fasting blood glucose and HbA1c. However, the magnitude of these effects has generally been modest, and study quality has varied considerably.

Key limitations in the existing evidence include:

• Small sample sizes, often fewer than 100 participants

• Short intervention durations, typically eight to twelve weeks

• Heterogeneity in GSE formulations and doses used across studies

• Lack of standardisation in background dietary and pharmacological treatment

• Risk of publication bias, which may overestimate positive findings

These factors make it difficult to draw firm conclusions or to generalise findings to broader patient populations. GSE cannot currently be recommended as a standalone intervention for improving HbA1c, and it should not be considered a substitute for evidence-based pharmacological or lifestyle treatment.

What the Research Says: Clinical Trials and Study Findings

Clinical trials and a 2022 systematic review suggest grape-derived polyphenols may modestly improve insulin sensitivity and fasting glucose, but overall evidence quality is rated low to moderate and no UK clinical guideline endorses GSE for glycaemic control.

A number of clinical trials have examined the effect of grape seed extract on glycaemic markers, including HbA1c, fasting plasma glucose, and insulin resistance indices. A randomised controlled trial published in Phytotherapy Research (Kar et al., 2013) found that GSE supplementation at 600 mg/day for eight weeks in patients with type 2 diabetes led to a statistically significant reduction in HbA1c compared to placebo, though the absolute magnitude of change and confidence intervals were modest and should be interpreted in the context of a small sample size and short duration. A meta-analysis published in 2016 pooled data from multiple trials and concluded that GSE supplementation was associated with a modest but statistically significant reduction in fasting blood glucose levels, though heterogeneity between studies was notable.

More recently, a 2022 systematic review examining polyphenol supplementation in type 2 diabetes noted that grape-derived polyphenols, including GSE, showed promise in improving insulin sensitivity and reducing oxidative stress biomarkers. However, the reviewers rated the overall quality of evidence as low to moderate using GRADE criteria, and concluded that larger, well-designed RCTs with adequate follow-up are needed before clinical recommendations can be made. No Cochrane review specific to GSE and glycaemic outcomes is currently available.

It is also worth noting that:

• Doses used in trials vary widely, typically ranging from 150 mg to 2,000 mg per day

• Bioavailability of OPCs differs between individuals and formulations, complicating dose-response interpretation

• Confounding factors such as diet, physical activity, and concurrent medication use are not always adequately controlled

• No UK clinical guideline endorses GSE for glycaemic control, regardless of these preliminary findings

In summary, while clinical trial data offer some support for a modest beneficial effect of GSE on blood glucose and potentially HbA1c, the evidence is not yet sufficiently robust to support formal clinical guidance. Patients and clinicians should interpret these findings with appropriate caution.

Safety, Side Effects, and Interactions to Be Aware Of

GSE is generally well tolerated but carries clinically important interaction risks with anticoagulants and antiplatelet drugs, and a theoretical hypoglycaemia risk alongside insulin or sulphonylureas; it is not MHRA-licensed and should be reported via the Yellow Card Scheme if adverse reactions occur.

Grape seed extract is generally considered well tolerated when taken at commonly studied doses. Most clinical trials have not reported serious adverse events. However, as with any supplement, there are important safety considerations that patients and healthcare professionals should be aware of before use.

Common side effects reported in some individuals include:

• Headache and dizziness

• Nausea or gastrointestinal discomfort

• Sore throat

Note that adverse event data for food supplements are generally limited, and the above list reflects findings from available clinical trials rather than a comprehensive pharmacovigilance dataset.

Of particular clinical relevance is the potential for drug interactions. GSE has antiplatelet properties, and there is a theoretical concern — based on limited human evidence — that it may potentiate the effects of anticoagulant or antiplatelet medications such as warfarin, aspirin, clopidogrel, and direct oral anticoagulants (DOACs) such as apixaban or rivaroxaban. Patients taking these medicines should seek medical advice before starting GSE, as the combination could theoretically increase bleeding risk. If you are due to have surgery or an invasive procedure, consider stopping GSE at least one to two weeks beforehand and inform your surgical team.

There is also a theoretical concern that GSE, if it does lower blood glucose, could contribute to hypoglycaemia when taken alongside insulin or sulphonylureas such as gliclazide. Whilst this has not been definitively demonstrated in clinical trials, it remains a prudent consideration. Patients on antidiabetic medication should inform their GP or diabetes care team before adding any supplement to their regimen.

Additional safety cautions:

• Pregnancy and breastfeeding: There is insufficient evidence to establish the safety of GSE during pregnancy or breastfeeding. It should be avoided unless specifically advised by a clinician.

• Children and adolescents (under 18 years): GSE is not recommended for use in children or adolescents due to a lack of safety data.

• Hepatic or renal impairment: Patients with significant liver or kidney disease should seek clinical advice before use, as metabolism and excretion of supplement constituents may be altered.

The Medicines and Healthcare products Regulatory Agency (MHRA) does not license GSE as a medicinal product in the UK, meaning it is sold as a food supplement and is not subject to the same rigorous pre-market safety and efficacy evaluation as licensed medicines. Quality and purity can vary between brands, so choosing products from reputable manufacturers with third-party testing is advisable.

If you experience any suspected side effects or adverse reactions after taking GSE, you can report these via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. This scheme helps the MHRA monitor the safety of medicines and supplements in the UK.

NHS and NICE Guidance on Supplements for Blood Sugar Management

Neither NHS nor NICE (NG28) recommends grape seed extract or any polyphenol supplement for managing type 2 diabetes or prediabetes; evidence-based lifestyle intervention and pharmacotherapy remain the standard of care.

Neither the NHS nor the National Institute for Health and Care Excellence (NICE) currently recommends grape seed extract — or any other polyphenol supplement — as part of the standard management pathway for type 2 diabetes or prediabetes. NICE guideline NG28 (Type 2 diabetes in adults: management) focuses on structured lifestyle interventions, evidence-based pharmacotherapy (including metformin as first-line treatment), and regular HbA1c monitoring as the cornerstones of glycaemic management.

NICE does acknowledge the role of dietary patterns in blood glucose control, and there is good evidence supporting high-fibre, low-glycaemic-index diets rich in plant-based foods — including fruits and vegetables that naturally contain polyphenols. However, this is distinct from recommending concentrated supplement forms of these compounds.

For individuals with prediabetes or those at high risk of developing type 2 diabetes, NICE guidance on prevention (previously PH38; refer to the current NICE guidance on type 2 diabetes prevention in adults at high risk for the most up-to-date recommendations) supports referral to the Healthier You: NHS Diabetes Prevention Programme (NHS DPP), which focuses on structured education, dietary modification, and increased physical activity. There is no provision within this pathway for supplement use.

Patients should be aware that:

• Supplements are not a substitute for prescribed medication or lifestyle change

• Self-treating with supplements without informing a healthcare professional may delay appropriate medical care

• Regular HbA1c monitoring remains essential for anyone with diabetes or at risk of it, regardless of supplement use

Useful NHS and NICE resources include:

• NICE NG28: Type 2 diabetes in adults: management (nice.org.uk/guidance/ng28)

• NHS HbA1c test information (nhs.uk)

• Healthier You: NHS Diabetes Prevention Programme (england.nhs.uk/diabetes/diabetes-prevention)

If you are considering any supplement for blood sugar management, discuss this with your GP, practice nurse, or diabetes specialist before starting.

Should You Consider Grape Seed Extract Alongside Prescribed Treatment?

GSE may be considered as a potential adjunct to evidence-based care for motivated patients without contraindications, but it must not replace prescribed treatment and should only be started after discussion with a GP or diabetes care team.

For individuals already receiving treatment for type 2 diabetes or prediabetes, the decision to add grape seed extract to their regimen should be made thoughtfully and in consultation with their healthcare team. The existing evidence, whilst preliminary and of interest, does not yet meet the threshold required for formal clinical endorsement. GSE should therefore be viewed as a potential adjunct — not a replacement — for evidence-based care.

For patients who are motivated to explore complementary approaches and who have no contraindications (such as anticoagulant use, known grape allergy, pregnancy, breastfeeding, or significant hepatic or renal impairment), GSE may be a reasonable addition to a broader healthy lifestyle strategy. A diet naturally rich in polyphenols — including berries, dark chocolate, green tea, and grapes themselves — is broadly consistent with dietary guidance for metabolic health and carries fewer uncertainties than concentrated supplementation.

GSE should be avoided in:

• Pregnancy and breastfeeding

• Children and adolescents under 18 years

• Individuals on anticoagulant or antiplatelet therapy, unless a clinician has reviewed the risks

• Those with significant hepatic or renal impairment, without clinical advice

When to contact your GP or diabetes care team:

• If you experience unexplained episodes of low blood sugar (hypoglycaemia)

• If your HbA1c worsens despite lifestyle efforts and supplement use

• If you are taking anticoagulants, antiplatelets, or insulin and wish to start GSE

• If you notice any new or unusual symptoms after starting a supplement

When to seek urgent medical help:

• Severe hypoglycaemia (e.g., loss of consciousness, seizure, or inability to treat yourself)

• Symptoms of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS), such as extreme thirst, vomiting, confusion, or rapid breathing — call 999 or go to your nearest A&E

In conclusion, grape seed extract represents an area of genuine scientific interest in the context of blood sugar management and HbA1c reduction. However, the current evidence base is insufficient to support its routine clinical use. Patients are encouraged to maintain open communication with their healthcare providers, prioritise NICE-recommended interventions, and approach supplement use with informed, realistic expectations. Suspected adverse reactions should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions